Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
Date:2/17/2011

on at www.provenge.com or call Dendreon ON Call at 1-877-336-3736

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics.  The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types.  Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.  Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers.  The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN.  For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including commercialization of PROVENGE.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.  Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release.
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... Johnston, RI (PRWEB) January 22, 2015 ... State , The growing team of brand-neutral, independent consultants, ... CIO Philip Rogers explained that over the years, his ... including , Moroso, Town of Plainfield, as well as ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... Medical Systems (NYSE: VAR ), world leader in ... to sustainability with inclusion on a prestigious list of the ... equipment company among the Corporate Knights Global 100 Most Sustainable ... Davos, Switzerland . "We ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... CHAPEL, Florida, March 20 NexGen,Biofuels Ltd. (OTC:NXGNF) ... its ordinary shares have been approved for quotation ... NexGen is a development stage company that is ... plants and blending assets in,the United States., ...
... increasing physician acceptance of electrophysiology ablation ... fibrillation, according to ... According to Millennium,Research Group,s Global Markets for Atrial Fibrillation ... were,performed for the treatment of AF in the US ...
... LUMEDX Corporation, a leading,provider of fully integrated ... version of its real-time patient and resource,scheduler ... physicians, staff, rooms with drag and drop ... and,substantial ROI., A free CardioSchedule Information ...
Cached Biology Technology:Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25% Annually Over the Next Five Years 2LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems 2
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
(Date:12/22/2014)...  The 2014 Holiday Season may be the brightest ever ... that the long anticipated floodgates for consumer biometrics may ... smart phones, tablets, and wearable mobile devices that incorporate ... users with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... Power ... Consumption, TUSTIN, ... high-performance module designed for connecting,devices that require low power consumption to ... applications that need,WLAN connectivity with minimal power usage, such as battery-operated,portable ...
... WASHINGTON -- A new NASA-led study shows human-caused climate ... of Earth,s natural systems, including permafrost thawing, plants blooming ... Africa. Cynthia Rosenzweig of NASA,s Goddard Institute ... 10 other institutions have linked physical and biological impacts ...
... May 13, 2008.-Unlike most scientific and technological advances, which ... often finds itself the center of public debate and ... by many of its applications. , In this ... (the first was in 2003), the sample has been ...
Cached Biology News:New Silex SX-560 Enables Enterprise 802.11 Wireless Connectivity for Battery Operated Devices 2NASA study links Earth impacts to human-caused climate change 2BBVA Foundation international study on attitudes to stem cell research 2BBVA Foundation international study on attitudes to stem cell research 3BBVA Foundation international study on attitudes to stem cell research 4BBVA Foundation international study on attitudes to stem cell research 5BBVA Foundation international study on attitudes to stem cell research 6
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Request Info...
Homo sapiens olfactomedin 1, transcript variant 3...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Biology Products: